ISDA

Deposition Date 2022-03-10

Release Date 2022-05-25

Last Version Date 2024-10-23

Entry Detail

PDB ID:

7X7O

Keywords:

VIRAL PROTEIN

Title:

SARS-CoV-2 spike RBD in complex with neutralizing antibody UT28K

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)
Homo sapiens (Taxon ID: 9606)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

3.75 Å

R-Value Free:

0.33

R-Value Work:

0.30

R-Value Observed:

0.30

Space Group:

I 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:A, B, C, D
Chain Length:215
Number of Molecules:4
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Polymer Type:polypeptide(L)
Molecule:UT28K Fab, heavy chain
Chain IDs:E, G, H, J
Chain Length:257
Number of Molecules:4
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:UT28K Fab, light chain
Chain IDs:F, I, K, L
Chain Length:235
Number of Molecules:4
Biological Source:Homo sapiens

Ligand Molecules

Primary Citation

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.

Ozawa, T, Tani, H, Anraku, Y, Kita, S, Igarashi, E, Saga, Y, Inasaki, N, Kawasuji, H, Yamada, H, Sasaki, S.I, Somekawa, M, Sasaki, J, Hayakawa, Y, Yamamoto, Y, Morinaga, Y, Kurosawa, N, Isobe, M, Fukuhara, H, Maenaka, K, Hashiguchi, T, Kishi, H, Kitajima, I, Saito, S, Niimi, H.Show

Mabs 14 2072455 2072455 (2022)

PMID: 35543180 DOI: 10.1080/19420862.2022.2072455

Abstact

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Legend

Protein

Chemical

Disease

Primary Citation of related structures